



This is an English translation of a Hebrew immediate report that was published on April 12, 2022 (Ref No.: 2022-01-046879) (hereafter: the “**Hebrew Version**”). This English version is only for convenience purposes. This is not an official translation and has no binding force. Whilst reasonable care and skill have been exercised in the preparation hereof, no translation can ever perfectly reflect the Hebrew Version. In the event of any discrepancy between the Hebrew Version and this translation, the Hebrew Version shall prevail.

BEEIO HONEY LTD

(the “**Company**”)

April 12, 2022

To:
Israel Securities Authority
www.isa.gov.il

To:
Tel Aviv Stock Exchange Ltd .
www.tase.co.il

Dear Sirs and Madams,

Re: Beeio Honey Technologies Ltd. was successful in producing cultured royal jelly protein in an accurate fermentation process using a bioreactor as a preliminary stage for mass production and also successfully completed an experiment proving that the protein has antibacterial properties

The Company is honored to inform its shareholders that further to the Company's report of December 20, 2021 (Ref No. 2021-01-182055), in which it reported of its success in an experiment to express a cultured royal jelly protein, on April 12, 2022 Beeio Honey Technologies Ltd., a private company fully owned by the Company (hereinafter: the “**Subsidiary**”), informed of its success in producing cultured royal jelly protein using an advanced biological growth vessel called bioreactor and also successfully completed an experiment to determine the antibacterial properties of the cultured royal jelly protein produced in its facilities (hereinafter: the “**Experiment**”).

The successful Experiment proves that the Subsidiary is capable of producing a cultured royal jelly protein with proven antibacterial properties in an efficient, consistent manner using a bioreactor. The production capability by means of the bioreactor is a vital condition and constitutes a preliminary stage to the development of mass production technology of cultured products. Therefore, in the Company's opinion, the successful Experiment is a significant milestone in promoting the Subsidiary towards the goal of developing mass growth capability of a cultured royal jelly protein with antibacterial properties.



A cultured royal jelly protein is a component contained in pure honey originating from bees. This protein has broad uses for man in the food industry, in medicine, and in cosmetics¹. In addition, according to external sources, researches attribute a broad variety of pharmaceutical properties to this protein in human medicine, such as healing wounds, anti-bacterial and antifungal properties, decreasing cholesterol levels, lowering blood sugar levels, anti-cancerous properties, expansion of blood vessels, decreasing high blood pressure, and increasing the activity of the immune system². Cultured royal jelly protein, without the use of bees, is an additional significant milestone in the development of cultured honey, as a commodity in itself and as nutritional supplement to other products.

The success in the Experiment is in accordance with the work plan that was concluded by the Company and the Subsidiary, and is expected to allow the Subsidiary to continue developing mass production capabilities of cultured honey and additional commodities. The Company evaluates that some of the findings and/or processes and/or research methods which may be developed, should the Company and the Subsidiary successfully meet the goals they have set, could at the very least be used as intellectual property base in addition to the currently existing intellectual property.

The information mentioned in this notice is “Forward Looking Information” as defined in the Securities Law, 5728-1968 and the regulations under it, based on the information known to the Company as of this date, and on estimates and predictions which their realization depends, among others, on factors that are outside of the Company’s control, as stated in this report above. To be noted, the Company is a research and development company and as such, its estimations might be realized in a different manner, if at all, given that the Company’s research is preliminary and precedential.

Sincerely,
OFIR DVASH, CEO
BEEIO HONEY LTD

¹ For further details regarding the use of the royal jelly protein in the food, medical and cosmetics industries, see the following link: <https://dataintel.com/report/royal-jelly-market/>

² For further details regarding the pharmaceutical activity of the royal jelly protein in human medicine, see the following link: <https://www.nature.com/articles/s41467-018-05619-1>